Following similar moves by many of its Big Pharma peers, GlaxoSmithKline PLC is buying into large molecules, big time. In December 2006, it paid £230mm ($454 million) in cash for next-generation antibody specialist Domantis Ltd.[See Deal] Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for Genmab AS ' HuMax-CD20 (ofatumumab) fully human monoclonal antibody, plus other anti-CD20 antibodies that GenMab may develop. [See Deal](See "Genmab/GSK: An Impressive Display of Biotech’s Increased Leverage," IN VIVO, January 2007 Also see "Genmab/GSK: An Impressive Display of Biotech's Increased Leverage" - In Vivo, 1 January, 2007..)
The Domantis acquisition was GSK’s first external transaction in the area and a direct consequence of an internal review by...







